Literature DB >> 6370760

Insulin antibodies in diabetic children treated with monocomponent porcine insulin from the onset: relationship to B-cell function and partial remission.

J Ludvigsson.   

Abstract

Insulin antibodies expressed as insulin binding capacity of IgG were determined in 50 Type 1 (insulin-dependent) diabetic children who have been treated with monocomponent porcine insulin from the onset of the disease. During the follow-up period of 0.5-5.5 years (mean +/- SD: 3.2 +/- 1.6 years), 26 out of 50 patients (52%) developed detectable insulin antibodies. These patients had significantly lower maximal C-peptide responses to a standardized breakfast 9 months after onset of diabetes (mean 0.24 pmol/ml, p less than 0.001) than those without insulin antibodies (mean 0.47 pmol/ml). In addition, patients with antibodies showed both significantly higher insulin requirements at 9 months (p less than 0.05), and shorter remissions (p less than 0.01) than those without. It is concluded that even 'small' amounts of insulin antibodies may be biologically significant and have negative effects on B-cell function and metabolic balance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370760     DOI: 10.1007/bf00281121

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  17 in total

1.  Immune reactions to fractions of crystalline insulin. II. May peri-insulitis be produced by an antigen different from true Sanger insulin?

Authors:  F K Jansen; G Freytag
Journal:  Diabetologia       Date:  1973-06       Impact factor: 10.122

2.  Immune reactions to fractions of crystalline insulin. I. Significance of lymphocytic infiltrates in the endocrine and exocrine pancreas of mice.

Authors:  G Freytag; F K Jansen; G Klöppel
Journal:  Diabetologia       Date:  1973-06       Impact factor: 10.122

3.  Simple test for insulin antibodies in sera, using 131-I-insulin and ethanol precipitation.

Authors:  T A Welborn; R Richards; T R Fraser
Journal:  Br Med J       Date:  1967-03-25

4.  Radioimmunoelectrophoresis in the determination of insulin binding to IgG.

Authors:  A H Christiansen
Journal:  Horm Metab Res       Date:  1973-05       Impact factor: 2.936

5.  Enhancement of glucose-stimulated insulin secretion from isolated rat pancreatic islets by human insulin antibodies.

Authors:  H J Hahn; R Menzel; H D Gottschling; D Jahr
Journal:  Acta Endocrinol (Copenh)       Date:  1976-09

6.  The immunogenicity of insulin preparation. Antibody levels before and after transfer to highly purified porcine insulin.

Authors:  L G Heding; Y Larsson; J Ludvigsson
Journal:  Diabetologia       Date:  1980       Impact factor: 10.122

7.  Insulin antibodies in the serum of diabetic children treated from the diagnosis of the disease with highly purified insulins.

Authors:  H K Akerblom; A L Mäkelä
Journal:  Acta Paediatr Scand Suppl       Date:  1977

8.  Diabetes mellitus in rabbits immunized with insulin.

Authors:  G M Grodsky; R Feldman; W E Toreson; J C Lee
Journal:  Diabetes       Date:  1966-08       Impact factor: 9.461

9.  beta-cell function in children with diabetes.

Authors:  J Ludvigsson; L G Heding
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

10.  C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control.

Authors:  J Ludvigsson; L G Heding; Y Larsson; E Leander
Journal:  Acta Paediatr Scand       Date:  1977-03
View more
  12 in total

1.  Human insulin.

Authors:  J Pickup
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-18

2.  Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis.

Authors:  M Wallensteen; G Dahlquist; B Persson; M Landin-Olsson; A Lernmark; G Sundkvist; B Thalme
Journal:  Diabetologia       Date:  1988-09       Impact factor: 10.122

3.  Insulin autoantibodies are associated with islet cell antibodies; their relation to insulin antibodies and B-cell function in diabetic children.

Authors:  J Ludvigsson; C Binder; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  1988-09       Impact factor: 10.122

4.  Comparison of human and porcine insulin therapies in children with newly diagnosed diabetes mellitus.

Authors:  K Zuppinger; C Aebi; S Fankhauser; G Herz; R P Zurbrügg; K Schopfer; T M Neri
Journal:  Diabetologia       Date:  1987-12       Impact factor: 10.122

5.  Prevalence of residual B-cell function related to age at onset and genetic profile in newly diagnosed type I diabetics.

Authors:  C Giordano; A Galluzzo; F Pantò; C Caruso; G Bompiani
Journal:  Acta Diabetol Lat       Date:  1987 Oct-Dec

Review 6.  Immunological aspects on IDDM in children.

Authors:  J Ludvigsson
Journal:  Indian J Pediatr       Date:  1989 Nov-Dec       Impact factor: 1.967

7.  Immunogenicity of monocomponent human and porcine insulin in newly diagnosed type 1 (insulin-dependent) diabetic children.

Authors:  L G Heding; M O Marshall; B Persson; G Dahlquist; B Thalme; F Lindgren; H K Akerblom; A Rilva; M Knip; J Ludvigsson
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

Review 8.  Insulin-dependent (type I) diabetes mellitus.

Authors:  W Rodger
Journal:  CMAJ       Date:  1991-11-15       Impact factor: 8.262

9.  Relationship between serum insulin autoantibodies, islet cell antibodies and Coxsackie-B4 and mumps virus-specific antibodies at the clinical manifestation of type 1 (insulin-dependent) diabetes.

Authors:  J Karjalainen; M Knip; H Hyöty; P Leinikki; J Ilonen; M L Käär; H K Akerblom
Journal:  Diabetologia       Date:  1988-03       Impact factor: 10.122

10.  Insulin autoantibodies at the clinical manifestation of type 1 (insulin-dependent) diabetes--a poor predictor of clinical course and antibody response to exogenous insulin.

Authors:  J Karjalainen; M Knip; A Mustonen; H K Akerblom
Journal:  Diabetologia       Date:  1988-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.